EVERJOY HEALTH(002162)
Search documents
悦心健康(002162) - 2018年3月5日投资者关系活动记录表
2022-12-04 08:48
证券代码:002162 证券简称:悦心健康 上海悦心健康集团股份有限公司投资者关系活动记录表 编号:201801 | --- | --- | --- | |-----------------------|--------------------------|----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | √ \n□ \n□ □ 现场参观 \n□ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 | 广发证券 徐笔龙 | | | 及人员姓名 | 国海证券 陈晨 | | | | 海通证券 师成平、张咪 | | | | 上海哈平投资 王仲明 | | | | 西南证券 张肖星 | | | | 兴业证券 杨子颉 | | | 时间 | 2018 年 3 月 5 | 日 13:00-15:00 | | 地点 | 上海市闵行区恒南 ...
悦心健康(002162) - 悦心健康调研活动信息
2022-12-03 10:56
编号:201904 证券代码:002162 证券简称:悦心健康 上海悦心健康集团股份有限公司 2019 年 9 月 5 日投资者关系活动记录表 | --- | --- | --- | |---------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | √ \n□ \n□ □ 现场参观 \n□ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | | 海通证券股份有限公司研究所 潘莹练 | | 时间 | 2019 年 9 月 5 | 日 15:00 | | 地点 | 上海市黄浦区中山南一路 | 893 号公司会议室 | | 上市公司接待 人员姓名 | 陈前、程梅、王小莹、马冰帅 | | | 投资者关系活 动主 ...
悦心健康(002162) - 悦心健康调研活动信息
2022-12-03 10:22
编号:201903 证券代码:002162 证券简称:悦心健康 上海悦心健康集团股份有限公司 2019 年 6 月 19 日投资者关系活动记录表 | --- | --- | --- | |---------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | √ \n□ □现场参观 \n□ | 特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | 国信证券:何嘉、尹冠钧 | | | 时间 | 2019 年 6 月 19 | 日 15:00 | | 地点 | 上海市闵行区浦江镇恒南路 | 1288 号 5 楼会议室 | | 上市公司接待 人员姓名 | 程梅、马冰帅 | | | 投资者关系活 动主要内容介 | 1. | 公 ...
悦心健康(002162) - 悦心健康调研活动信息
2022-12-03 10:20
编号:201901 证券代码:002162 证券简称:悦心健康 | --- | --- | --- | |---------------------------|----------------------------|----------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | 动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □ | 其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | | 海通证券股份有限公司研究所 潘莹练 | | 时间 | 2019 年 5 月 8 | 日 15:00 | | 地点 | 上海市闵行区浦江镇恒南路 | 1288 号会议室 | | 上市公司接待 人员姓名 | 程梅、陈前、徐泰龙、王小莹 | | | 投资者关系活 动主要内容介 | 1 | 、公司瓷砖销售客户中地产、经销商和直销占比分别是多大比 | | | | | | 绍 | | 例?未来重点 ...
悦心健康(002162) - 悦心健康调研活动信息
2022-12-03 10:18
编号:201902 证券代码:002162 证券简称:悦心健康 | --- | --- | --- | |---------------------------|-------------------------|-----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | √ \n□ \n□现场参观 □ | 特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | | 浩铠资产管理(上海)有限公司 刘杰锋 | | 时间 | 2019 年 5 月 23 | 日 15:00 | | 地点 | | 上海市闵行区浦江镇恒南路 1288 号会议室 | | 上市公司接待 人员姓名 | 程梅、王小莹 | | | 投资者关系活 动主要内容介 | 一、公司简介: | | | 绍 | 公司成立于 | 1993 年,目前的业务主要包括建筑陶 ...
悦心健康(002162) - 2018年6月14日投资者关系活动记录表
2022-12-03 09:52
编号:201803 证券代码:002162 证券简称:悦心健康 上海悦心健康集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |---------------------------|--------------------------|----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □ \n√ \n□ \n□ 现场参观 □ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | 中国经营报记者 李静 | | | 时间 | 2018 年 6 月 14 | 日 15:00 | | 地点 | | 本次公司接受媒体采访主要通过邮件往来的书面形式进行 | | 上市公司接待 人员姓名 | | 程梅、宋源诚、徐泰龙、杨明华、王小莹 | | 投资者关系活 动主要内容介 | 2018 年 6 ...
悦心健康(002162) - 2018年6月8日投资者关系活动记录表
2022-12-03 09:50
证券代码:002162 证券简称:悦心健康 上海悦心健康集团股份有限公司投资者关系活动记录表 编号:201802 | --- | --- | --- | |---------------------------|--------------------------|----------------------------------------------------------------------------------------------------------| | 投资者关系活 \n动类别 | □ \n√ \n□ \n□ 现场参观 □ | 特定对象调研 □分析师会议 \n媒体采访 □业绩说明会 \n新闻发布会 □路演活动 \n其他 (请文字说明其他活动内容) | | 参与单位名称 及人员姓名 | 长江商报记者 徐佳 | | | 时间 | 2018 年 6 月 8 | 日 16:00 | | 地点 | | 本次公司接受媒体采访主要通过邮件往来的书面形式进行 | | 上市公司接待 人员姓名 | | 程梅、宋源诚、徐泰龙、杨明华、戴珏、王小莹 | | 投资者关系活 动主要内容介 | 2018 年 6 ...
悦心健康(002162) - 2022 Q3 - 季度财报
2022-10-27 16:00
上海悦心健康集团股份有限公司 2022 年第三季度报告 证券代码:002162 证券简称:悦心健康 公告编号:2022-037 1 上海悦心健康集团股份有限公司 2022 年第三季度报告 一、主要财务数据 上海悦心健康集团股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整,不存在虚假记载、误导性陈述或重大 遗漏,并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明:保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入(元) | 350,184,017.80 | 3.67 ...
悦心健康(002162) - 2022 Q2 - 季度财报
2022-08-14 16:00
Financial Performance - The company's operating revenue for the first half of 2022 was ¥499,494,322.11, a decrease of 11.38% compared to ¥563,606,307.04 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was -¥8,608,801.93, representing a decline of 134.81% from ¥24,731,536.29 in the previous year[21]. - The net cash flow from operating activities was -¥21,353,745.01, a significant drop of 1,505.54% compared to ¥1,519,254.16 in the same period last year[21]. - The basic earnings per share were -¥0.0093, down 132.07% from ¥0.0290 in the previous year[21]. - The total operating revenue for the reporting period was ¥499,494,322.11, a decrease of 11.38% compared to ¥563,606,307.04 in the same period last year[57]. - The company reported a net loss of ¥11,254,999.01 from Shanghai Simic Building Materials Co., Ltd., indicating challenges in its subsidiary operations[72]. - The company reported a total profit of 3,520.40 million CNY from leasing assets, contributing over 10% to the total profit for the reporting period[119]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,682,525,475.06, a decrease of 1.12% from ¥2,712,784,671.26 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were ¥1,276,084,616.54, a slight decrease of 0.19% from ¥1,278,519,957.81 at the end of the previous year[21]. - As of June 30, 2022, cash and cash equivalents amounted to ¥270,361,958.34, representing 10.08% of total assets, a decrease of 2.71% from the previous year[63]. - Accounts receivable increased to ¥318,883,426.19, accounting for 11.89% of total assets, reflecting a 0.81% increase year-over-year[63]. - Inventory stood at ¥337,492,268.98, which is 12.58% of total assets, showing a 0.78% increase compared to the previous year[63]. - Short-term borrowings were reported at ¥412,823,421.18, constituting 15.39% of total assets, with no significant changes noted[63]. - The total liabilities of the company were not explicitly stated but can be inferred from the balance sheet data provided[146][147]. Revenue Segments - The company operates in four main business segments: building materials, health and wellness, medical services, and investment property leasing[29]. - The revenue from the ceramic and ecological building materials business was CNY 415 million, accounting for 83.17% of total revenue, with a year-on-year decline of approximately 15%[51]. - The health and wellness segment generated revenue of CNY 42 million, representing an increase of 4.64% year-on-year, indicating growth in the medical and elderly care services[51]. - The company achieved rental income of CNY 41.78 million from its industrial land, a year-on-year increase of 12%, with a total leased area of approximately 150,000 square meters[48]. Operational Strategies - The company plans to transform its industrial land into a smart healthcare innovation park, aligning with local government development plans for the area[49]. - The company is focusing on enhancing its medical beauty services and high-end elderly care facilities, aiming to establish itself as a leader in integrated healthcare services[46]. - The company is actively engaging with local government to advance the regulatory adjustments and transformation plans for its industrial land[50]. - The company is committed to continuous product innovation and development, focusing on eco-friendly materials and advanced technology in its offerings[42]. Environmental and Social Responsibility - The company has implemented environmental management systems and achieved significant reductions in pollutant emissions, with actual emissions for particulate matter at 4.89 mg/NM3, SO2 at 27.52 mg/NM3, and NOX at 46.01 mg/NM3, all below the respective standards[89]. - The company has a wastewater treatment system that ensures zero discharge, with treated wastewater meeting national standards[88]. - Jiangxi Simic invested approximately CNY 2.82 million in environmental protection expenses in the first half of 2022, covering waste disposal, environmental tax, and maintenance of environmental facilities[93]. - Jiangxi Simic's photovoltaic project generated 3.791 million KWH of electricity in the first half of 2022, reducing carbon emissions by 3,779.6 tons[94]. Future Outlook and Strategic Initiatives - The company plans to enhance its market expansion strategies, focusing on new product development and technological advancements[172]. - The company aims to improve its financial performance by implementing new strategies and optimizing existing operations[177]. - The future outlook remains cautious due to market volatility, but the company is optimistic about recovery in the second half of the year[167]. - The company has set a performance guidance for the next quarter, expecting a revenue growth of 5% to 10% compared to the current period[166].
悦心健康(002162) - 2021 Q4 - 年度财报
2022-04-26 16:00
Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2021, representing a year-on-year increase of 15%[14]. - The net profit attributable to shareholders was RMB 150 million, an increase of 10% compared to the previous year[14]. - The company's operating revenue for 2021 was CNY 1,260,831,976.72, an increase of 5.54% compared to CNY 1,194,703,084.49 in 2020[20]. - The net profit attributable to shareholders decreased by 19.27% to CNY 46,171,031.16 from CNY 57,195,036.74 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 28,772,012.05, down 18.19% from CNY 35,167,176.89 in 2020[20]. - The company's total assets increased by 8.44% to CNY 2,712,784,671.26 at the end of 2021, compared to CNY 2,501,558,406.84 at the end of 2020[20]. - The net assets attributable to shareholders rose by 23.53% to CNY 1,278,519,957.81 from CNY 1,034,970,311.17 in 2020[20]. - The company's cash flow from operating activities was CNY 153,243,763.30, a slight increase of 0.52% from CNY 152,455,604.70 in 2020[20]. - In 2021, the company achieved operating revenue of CNY 1.26 billion, a year-on-year increase of 5.54%[68]. - The health and wellness (medical and elderly care) business generated revenue of CNY 84 million, accounting for 6.69% of total revenue, with a growth of 0.28% compared to the previous year[68]. Market Expansion and Strategy - User data showed a growth in active users by 20%, reaching a total of 500,000 users by the end of 2021[14]. - The company plans to expand its market presence by opening 10 new health management centers in 2022[14]. - Future guidance indicates a revenue target of RMB 1.5 billion for 2022, reflecting a growth rate of 25%[14]. - The company aims to enhance its digital health services, with a projected increase in online consultations by 30% in 2022[14]. - The company is expanding its health care services to meet the diverse needs of high-net-worth seniors, providing a comprehensive care system[46]. - The company plans to develop a dual-brand strategy, focusing on "Simik" for stylish health building materials and "Yuexin" for healthcare services, aiming to establish a leading enterprise in the integrated healthcare sector[118]. - The company aims to expand its channels for old community renovations and secondary renovations, which are expected to be major battlegrounds for building material brands[119]. - The company will focus on developing retail channels for integrated home decoration and designer sales, enhancing collaboration with these resources to increase retail market share[120]. Research and Development - The company is investing RMB 100 million in R&D for new health technology products in 2022[14]. - The company developed over 40 new products in 2021, with new product sales accounting for nearly 17% of total revenue[60]. - The company completed the development of the "Yin Guang" series, enhancing product competitiveness and aligning with market trends[84]. - The "Morandi Simon" series was also completed, improving overall product competitiveness and meeting customer demands[84]. - The number of R&D personnel increased by 1.70% to 239, with a slight decrease in the proportion of R&D personnel to total employees[85]. Operational Challenges - The company faced challenges due to rising costs and market competition, leading to a significant impact on profit margins[30]. - The company anticipates challenges from fluctuating raw material and energy prices, which could affect profitability if costs continue to rise[125]. - The company is exploring new strategies in the healthcare and elderly care sectors to mitigate risks associated with changing national policies[125]. Environmental and Social Responsibility - The company achieved a significant reduction in emissions, with actual discharge data for particulate matter at 4.39 mg/Nm³, SO2 at 18.76 mg/Nm³, and NOX at 36.45 mg/Nm³, representing a total emission reduction of approximately 53% compared to previous levels[182]. - The company has established a comprehensive environmental management system, including quality, environment, energy, and occupational health safety management systems, which are certified annually[178]. - The wastewater treatment process ensures that production wastewater is treated to meet national standards, achieving zero discharge through multiple sedimentation processes[181]. - The company emphasizes the importance of social responsibility and environmental protection in its operational practices[177]. - Jiangxi Smick Ceramics Co., Ltd. invested a total of 5.6007 million CNY in environmental protection expenses in 2021, including waste disposal fees, environmental taxes, and maintenance costs[186]. Corporate Governance - The company has established a comprehensive internal control management system to ensure compliance and effectiveness in operations[167]. - The internal control audit report confirmed that the company maintained effective internal controls related to financial statements as of December 31, 2021[172]. - The company’s governance structure includes a board of directors, supervisory board, and various committees to ensure effective oversight[168]. - The company has a diverse management team with backgrounds in finance, engineering, and law, enhancing its operational capabilities[135][136][137][138]. Employee Management - The total number of employees at the end of the reporting period was 920, with 111 in the parent company and 809 in major subsidiaries[160]. - The employee composition includes 411 sales personnel, 270 production personnel, 92 technical personnel, 46 financial personnel, and 101 administrative personnel[160]. - The company emphasizes a performance management system that combines regular and irregular assessments to determine salary and bonus distributions[161]. - In 2021, the company conducted training for the sales team and distributors on new product releases and product knowledge[162]. Leadership Changes - The company appointed Song Yuancheng as the new President on September 28, 2021, following the resignation of Li Cixiong from the position[133]. - Li Cixiong remains as Chairman after stepping down as President to focus on strategic management and overall business control[134].